Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 p.m. E.T. Interested parties can access both live and archived versions of the presentation through the News & Events page in the Investors section of the Apogee Therapeutics website.
Positive
- None.
Negative
- None.
News Market Reaction – APGE
On the day this news was published, APGE gained 0.47%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://www.apogeetherapeutics.com/.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Apogee Therapeutics (APGE) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Apogee Therapeutics' (APGE) Guggenheim Conference presentation?
What type of presentation will APGE deliver at the Guggenheim SMID Cap Biotech Conference?
Will there be a replay available of APGE's Guggenheim Conference presentation?
